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Burden of Bloodstream Infection Caused by Extended-Spectrum 
/3-Lactamase-Producing Enterobacteriaceae Determined Using 
Multistate Modeling at a Swiss University Hospital and 
a Nationwide Predictive Model 
Andrew Stewardson, MBBS;1 Carolina Fankhauser, MS;1 Giulia De Angelis, MD;2 Peter Rohner, PhD;3 
Edith Safran, MD;3 Jacques Schrenzel, MD;4 Didier Pittet, MD;1 Stephan Harbarth, MD1 
OBJECTIVE. To obtain an unbiased estimate of the excess hospital length of stay (LOS) and cost attributable to extended-spectrum j3-
lactamase (ESBL) positivity in bloodstream infections (BSIs) due to Enterobacteriaceae. 
DESIGN. Retrospective cohort study. 
SETTING. A 2,200-bed academic medical center in Geneva, Switzerland. 
PATIENTS. Patients admitted during 2009. 
METHODS. We used multistate modeling and Cox proportional hazards models to determine the excess LOS and adjusted end-of-LOS 
hazard ratio (HR) for ESBL-positive and ESBL-negative BSI. We estimated economic burden as the product of excess LOS and average 
bed-day cost. Patient-level accounting data provided a complementary analysis of economic burden. A predictive model was fitted to 
national surveillance data. 
RESULTS. Thirty ESBL-positive and 96 ESBL-negative BSI cases were included. The excess LOS attributable to ESBL-positive and ESBL-
negative BSI was 9.4 (95% confidence interval [CI], 0.4-18.4) and 2.6 (95% CI, 0.7-5.9) days, respectively. ESBL positivity was therefore 
associated with 6.8 excess days and CHF 9,473 per BSI. The adjusted end-of-LOS HRs for ESBL-positive and ESBL-negative BSI were 0.62 
(95% CI, 0.43-0.89) and 0.90 (95% CI, 0.74-1.10), respectively. After reimbursement, the average financial loss per acute care episode in 
ESBL-positive BSI, ESBL-negative BSI, and control cohorts was CHF 48,674, 48,131, and 13,532, respectively. Our predictive model estimated 
that the nationwide cost of third-generation cephalosporin resistance would increase from CHF 2,084,000 in 2010 to CHF 3,526,000 in 
2015. 
CONCLUSIONS. This is the first hospital-wide analysis of excess LOS attributable to ESBL positivity determined using multistate modeling 
to avoid time-dependent bias. These results may inform health-economic evaluations of interventions targeting ESBL control. 
Infect Control Hosp Epidemiol 2013;34(2):133-143 
The past 2 decades have witnessed a rapid global increase in is the key driver of its cost from the hospital perspective.7"9 
extended-spectrum /3-lactamase (ESBL) production by En- Estimation of this figure, however, is hampered by several 
terobacteriaceae causing both healthcare- and community- methodological challenges.410 An accurate estimation must 
associated infections.1,2 ESBLs threaten the utility of com- account for the competing risks of death and increased LOS511 
monly used empiric antibiotic therapy and have been and for time-dependent bias.12 Failing to explicitly address 
associated with both delayed initiation of appropriate anti- the timing and onset of infection will always result in an 
biotic therapy and excess mortality.3"6 It is important to gain overestimation of the attributable hospital LOS and therefore 
an accurate appreciation of the economic burden of ESBL- of cost.101314 Multistate models account for competing out-
producing bacteria to justify the prioritization of infection comes and time-dependent bias1115 and have not been used 
control and antibiotic stewardship interventions required to to evaluate the burden of infection by ESBL-positive organ-
confront this problem.7 isms outside the intensive care context.16 
The excess length of stay (LOS) associated with an infection The primary aim of this study was to quantify the economic 
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FIGURE i. Representation of the multistate model adopted for this analysis. Every patient enters the model at state 0 (hospital admission, 
no bloodstream infection [BSI] detected). Death or final discharge from acute care is modeled by transition into state 2, which can occur 
with or without transition through state 1 (onset of BSI). ESBL, extended-spectrum /3-lactamase. 
burden attributable to ESBL production among Enterobac-
teriaceae by using multistate modeling to estimate excess LOS 
associated with bloodstream infection (BSI) due to ESBL-
positive and ESBL-negative isolates and then to extrapolate 
the excess cost due to ESBL positivity from the hospital per-
spective by using the average bed-day cost. The secondary 
aim was to develop a predictive model for the burden of 
third-generation cephalosporin resistance among Enterobac-
teriaceae causing BSIs throughout Switzerland. 
METHODS 
Setting and Study Design 
The University of Geneva Hospitals (HUG), a 2,200-bed pri-
mary and tertiary center, is the only major public hospital in 
the Swiss canton of Geneva and provides both acute and 
nonacute care to a population of 450,000 people. We studied 
3 parallel cohorts of patients admitted between January 1 and 
December 31, 2009: (1) those with BSI due to ESBL-positive 
Enterobacteriaceae, (2) those with BSI due to ESBL-negative 
Enterobacteriaceae, and (3) those without BSI due to Entero-
bacteriaceae. This was a retrospective, observational cohort 
study incorporating data from a prospective hospital-based 
BSI surveillance system.1718 Approval was granted by the In-
ternal Medicine Ethics Committee (HUG 11-022R). 
Definitions 
An inpatient episode was defined as the period of continuous 
hospitalization from admission from outside HUG (or birth 
for newborns) until the last day of acute care (terminated by 
discharge, transfer, or death) and could include days in acute 
and nonacute care. Inpatient episodes consisting entirely of 
nonacute or psychiatric care were excluded. A BSI was defined 
as culture of any Enterobacteriaceae from at least 1 blood 
culture bottle and was designated primary or secondary ac-
cording to Centers for Disease Control and Prevention def-
initions.19 The date of infection was defined as the first day 
the BSI criteria were met. ESBL-positive BSI and ESBL-neg-
ative BSI were defined, respectively, as BSI due to ESBL-
positive and ESBL-negative Enterobacteriaceae. Inadequate 
initial antimicrobial therapy was defined as the failure to 
prescribe an antimicrobial agent that was appropriate for the 
treatment of BSI and to which the infecting organism was 
susceptible within 24 hours of the time of the BSI. Healthcare-
associated and community-acquired infections were distin-
guished as defined elsewhere.20 
Patient Populations and Data Collection 
The first cohort consisted of all inpatients with an ESBL-
positive BSI during the study period. For each ESBL-positive 
patient, 3 patients with ESBL-negative BSI from the same 
ward were selected for inclusion in the second cohort. Mul-
tiple episodes of BSI for the same patient were included only 
if subsequent infections were not considered a relapse or the 
persistence of a previous episode. Patients were excluded if 
treatment with curative intent was not undertaken. For all 
patients with BSI, data on the following potential confound-
ing covariates were collected: age, sex, hospital location at 
date of infection, healthcare-associated or community-
acquired infection, infection site, bacterial species, adequacy 
of initial antibiotic treatment, intensive care unit (ICU) ad-
mission, and comorbid conditions on hospital admission. All 
ESBL-positive BSIs and all healthcare-associated ESBL-neg-
ative BSIs were prospectively included in a hospital-based BSI 
surveillance system. For patients with non-healthcare-asso-
ciated ESBL-negative BSI, data were obtained retrospectively 
from electronic patient records. 
The third cohort consisted of all patients with inpatient 
episodes commencing in 2009 during which a BSI due to 
Enterobacteriaceae did not occur. Data on age, sex, dates of 
discharge from acute ward or death, ICU admission, and 
surgical procedures were extracted retrospectively from elec-
tronic hospital records. This method was also used to validate 
surveillance data for the 2 BSI cohorts. 
Three predefined outcomes were examined: in-hospital 
mortality, excess LOS, and hospitalization costs measured 
from the hospital perspective. All included patients were ob-
served until discharge or in-hospital death. 
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TABLE i. Baseline Characteristics of Patients Experiencing Bloodstream Infections (BSIs) due to Enterobacteriaceae 
Characteristic 
Demographics 
Male sex 
Age, median ± SD, years 
Comorbidities 
Cardiovasular disease 
COPD 
Peripheral vascular disease 
Cerebrovascular disease 
Renal insufficiency 
Liver disease 
Diabetes without end-organ damage 
Diabetes with end-organ damage 
HIV 
Cancer 
Immunosuppression 
Peptic ulcer disease 
Connective tissue disease 
No commorbidity 
Epidemiological category 
Healthcare associated 
Community acquired 
Ward at BSI onset 
Medicine 
Surgery 
ICU 
Pediatrics 
Rehabilitation/geriatrics 
Gynecology/obstetrics 
Emergency 
Origin of infection 
Primary BSI 
Secondary BSI 
Bone and joint 
Cardiovascular system 
Gastrointestinal system 
Pneumonia or LRTI 
Reproductive tract 
Skin and soft tissue 
Surgical site infection 
Urinary tract 
ICU admission 
Pathogen 
Escherichia coli 
Klebsiella species 
Proteus species 
Enterobacter species 
Other Enterobacteriaceae 
ESBL production 
Inadequate initial antimicrobial therapy 
Infection 
Patients with 
ESBL BSI 
(« = 30) 
21 (70.0) 
62 ± 16 
3 (10.0) 
1 (3.3) 
3 (10.0) 
8 (26.7) 
2 (6.7) 
3 (10.0) 
10 (33.3) 
3 (10.0) 
0 (0) 
8 (26.7) 
7 (23.3) 
2 (6.7) 
0 (0) 
8 (26.7) 
16 (53.3) 
14 (46.7) 
7 (23.3) 
7 (23.3) 
1 (3.3) 
1 (3.3) 
3 (10.0) 
1 (3.3) 
10 (33.3) 
10 (33.3) 
20 (66.7) 
0 (0) 
0 (0) 
2 (6.7) 
0 (0) 
1 (3.3) 
0 (0) 
1 (3.3) 
17 (56.7) 
8 (26.7) 
25 (83.3) 
2 (6.7) 
0 (0) 
1 (3.3) 
2 (6.7) 
14 (46.7) 
Non-ESBL BSI 
(n = 96) 
60 (62.5) 
67 ± 19 
17 (17.7) 
4 (4.2) 
3 (3.1) 
11 (11.5) 
10 (10.4) 
14 (14.6) 
9 (9.4) 
4 (4.2) 
1 (1.0) 
33 (34.4) 
15 (15.6) 
1 (1.0) 
2 (2.1) 
28 (29.2) 
42 (43.8) 
54 (56.2) 
17 (17.1) 
20 (20.8) 
5 (5.2) 
2 (2.1) 
7 (7.3) 
4 (4.2) 
41 (42.7) 
23 (24.0) 
73 (76.0) 
1 (1.0) 
1 (1.0) 
13 (13.5) 
3 (3.1) 
1 (1.0) 
2 (2.1) 
3 (3.1) 
49 (51.0) 
21 (21.9) 
59 (61.5) 
18 (18.8) 
4 (4.2) 
8 (8.3) 
7 (7.3) 
24 (25.0) 
P 
.454 
.364 
.400 
.999 
.146 
.075 
.730 
.761 
.003 
.356 
.999 
.432 
.332 
.141 
.999 
.999 
.358 
.938 
.308 
.308 
.999 
.999 
.519 
.999 
.421 
.999 
.999 
.590 
.586 
.027 
.155 
.572 
.685 
.999 
.024 
Source 
Patients with 
HCA BSI 
(n = 58) 
36 (62.1) 
67 ± 13 
11 (19.0) 
3 (5.2) 
4 (6.9) 
9 (15.5) 
6 (10.3) 
4 (6.9) 
11 (19.0) 
4 (6.9) 
0 ( 0 ) 
25 (43.1) 
14 (24.1) 
0 (0.0) 
2 (3.5) 
12 (20.7) 
18 (31.0) 
21 (36.2) 
4 (6.9) 
0 ( 0 ) 
10 (17.2) 
1 (1.7) 
4 (6.9) 
24 (41.4) 
34 (58.6) 
0 ( 0 ) 
0 ( 0 ) 
5 (8.6) 
2 (3.5) 
0 ( 0 ) 
1 (1-7) 
4 (6.9) 
22 (37.9) 
18 (31.0) 
35 (60.3) 
12 (20.7) 
2 (3.5) 
5 (8.6) 
4 (6.9) 
16 (27.6) 
18 (31.0) 
CABSI 
(n = 68) 
45 (66.2) 
63 ± 21 
9 (13.2) 
2 (2.9) 
2 (2.9) 
10 (14.7) 
6 (8.8) 
13 (19.1) 
8 (11.8) 
3 (4.4) 
1 (1.5) 
16 (23.5) 
8 (11.8) 
3 (4.4) 
0 ( 0 ) 
24 (35.3) 
6 (8.8) 
6 (8.8) 
2 (2.9) 
3 (4.4) 
0 (0.0) 
4 (5.9) 
47 (69.1) 
9 (13.2) 
59 (86.8) 
1 (1.5) 
1 (1.5) 
10 (14.7) 
1 (1.5) 
2 (2.9) 
1 (1.5) 
0 ( 0 ) 
44 (64.7) 
11 (16.2) 
49 (72.1) 
8 (11.8) 
2 (2.9) 
4 (5.9) 
5 (7.4) 
14 (20.6) 
20 (29.4) 
P 
.632 
.008 
.380 
.661 
.413 
.899 
.772 
.045 
.260 
.702 
.999 
.019 
.068 
.249 
.210 
.070 
<.001 
<.001 
<001 
.999 
.999 
.293 
.594 
.499 
.999 
.042 
.003 
.048 
.164 
.172 
.999 
.731 
.999 
.358 
.843 
NOTE. Data are no. (%), unless otherwise indicated. CA, community acquired; COPD, chronic obstructive pulmonary 
disease; ESBL, extended-spectrum /3-lactamase; HCA, healthcare associated; HIV, human immunodeficiency virus; ICU, 
intensive care unit; LOS, length of stay; LRTI, lower respiratory tract infection; SD, standard deviation. 
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TABLE 2. Excess Length of Stay (LOS) and Hazard Ratios (HRs) for End of LOS Associated with Bloodstream 
Infection (BSI) due to Extended-Spectrum -^Lactamase (ESBL)-Positive and ESBL-Negative Enterobacteriaceae 
HR (95% CI) 
Excess LOS (95% CI), days Univariate Adjusted* 
ESBL-positive BSI (compared with no BSI) 9.4 (0.4-18.4)" 0.52 (0.36-0.76) 0.62 (0.43-0.89) 
ESBL-negative BSI (compared with no BSI) 2.6 (-0.7 to 5.9)c 0.75(0.62-0.92) 0.90(0.74-1.10) 
NOTE. CI, confidence interval. 
* Adjusted for age, sex, intensive care unit admission, and surgery. 
b
 In total, 30 ESBL-positive BSIs versus 96 ESBL-negative BSIs (censored at time of infection) and 42,476 patients 
without BSI due to Enterobacteriaceae. 
c
 In total, 96 ESBL-negative BSIs versus 30 ESBL-positive BSIs (censored at time of infection) and 42,476 patients 
without BSI due to Enterobacteriaceae. 
Microbiological Testing 
During the study period, blood culture specimens were in-
oculated into BACTEC Aerobic Plus/F and Lytic Anaerobic/ 
F vials and then incubated and monitored with the BACTEC 
9240 system (BD Diagnostic Systems). Microorganisms were 
identified using standard laboratory procedures. Antimicro-
bial susceptibilities and ESBL status were determined by the 
disk diffusion method, in accordance with Clinical and Lab-
oratory Standards Institute guidelines.21 ESBL confirmation 
was performed using a combination of 4 disks: cefotaxime 
versus cefotaxime/clavulanate and ceftazidime versus cefta-
zidime/clavulanate. Isolates were declared ESBL positive 
whenever the inhibition zone around the disk containing 
clavulanate was at least 5 mm larger than that of the disk 
containing the same cephalosporin but without clavulanate. 
Excess LOS Estimation 
A multistate model approach was used to estimate the excess 
LOS due to ESBL-positive BSI and ESBL-negative BSI, with 
excess LOS attributable to ESBL positivity then computed as 
the difference between the outputs of these 2 analyses. The 
occurrence of BSI was the time-dependent exposure, while 
final discharge from acute care (or in-hospital death) was the 
study end point (Figure 1). Patients with ESBL-negative BSI 
were administratively censored from the date of their infec-
tion when assessing LOS due to ESBL-positive BSI.15 Likewise, 
patients with ESBL-positive BSI were censored at infection 
onset when assessing LOS due to ESBL-negative BSI. Non-
parametric estimation of transition probabilities was per-
formed using the Aalen-Johansen estimator to provide the 
matrix of transition probabilities, as described elsewhere.11,15'22 
The mean difference in LOS (in days) was computed for each 
day as the difference between the predicted LOS given the 
intermediate state ("onset of BSI") being reached or not 
reached on that day. The overall change in LOS was then 
computed as an average of these quantities, weighted by the 
time to BSI among infected patients. Standard errors and 
confidence intervals (CIs) were derived by 500 bootstrap re-
sampling runs.15 
To compare the instantaneous risk of the 2 BSI cohorts 
reaching the end point (discharge from acute care or death), 
the end-of-LOS hazards over the course of time were cal-
culated. End-of-LOS hazard was defined as the number of 
discharged patients (dead or alive) on a given day divided by 
the number of patients still hospitalized at the beginning of 
that day. The Nelson-Aalen estimator was used to describe 
the cumulative transition hazards over the course of time.23 
To assess the independent effect of ESBL-positive and ESBL-
negative BSI on LOS, they were evaluated as time-dependent 
covariates using Cox proportional hazards models to estimate 
the end-of-LOS hazard ratio (HR). Variables for adjustment 
included age, sex, ICU admission, and surgery during the 
current hospitalization. 
LOS analysis was performed using R, version 2.10.1 (R 
Development Core Team), an open-source language for sta-
tistical computing and graphics. All other analyses were per-
formed using Stata, version 11 (StataCorp). 
Cost Estimation 
Total cost accounting charges were divided by the number of 
bed-days in acute and nonacute care to obtain an average 
cost of a hospital bed-day in 2009, excluding psychiatry. The 
excess cost due to ESBL positivity from the hospital per-
spective was estimated as the product of this average bed-
day cost and the excess LOS attributed to ESBL positivity 
during the study period.7 Costs were computed in 2009 Swiss 
francs (CHF). 
A concurrent patient-level cost analysis was performed. In 
2009, HUG used a microcosting system that identified and 
aggregated the variable- and fixed-cost components of patient 
activities, hospital services, and products according to the date 
of service.24,25 Each acute care episode was assigned a diag-
nosis-related group (DRG) according to the Swiss adaptation 
of the All Patient DRG system based on International Statis-
tical Classification of Diseases and Related Health Problems, 
10th Revision diagnostic codes,26 Classification Suisse des In-
terventions Chirurgicales (CHOP) intervention codes,27 and 
administrative data. Each DRG had an assigned "cost weight-
ing," a factor by which the base rate (approximately CHF 
12,000 for HUG in 2009) was multiplied to calculate the 
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TABLE 3. Nested Patient-Level Analysis of Costing and Coding Data for the Acute Care Stay of Patients with Extended-
Spectrum /3-Lactamase (ESBL)-Positive Bloodstream Infection (BSI), Patients with ESBL-Negative BSI, and Patients Matched 
with the ESBL-Positive Cohort on the Basis of Age, Sex, and Diagnosis-Related Group 
ESBL-positive BSI ESBL-negative BSI Matched cohort 
(n = 26) (n = 83) Pa (« = 49) Pa 
Episode-level data 
Age, median (IQR), years 62 (47-70) 68 (49-78) .069 64 (48-69) 
Male sex, no. (%) 19 (73.1) 53 (63.9) .480 36 (73.5) 
LOS, median (IQR), days 18.5 (14-38) 14 (7-27) .048 10 (5-20) .006 
Patient cost, median 
(IQR), CHF 38,175 (19,231-75,759) 31,322 (15,311-61,152) .402 24,576 (14,309^7,264) .136 
Case mix indexb 2.47 2.20 .879 2.68 .743 
Aggregate cohort data 
Total cost, CHF 2,035,455 6,187,937 2,240,540 
Casemix' 64.16 182.754 131.453 
Cost incurred per cost 
weight point, CHF 31,725 33,859 17,044 
NOTE. IQR, interquartile range; LOS, length of stay. 
" Testing the null hypothesis that there is no difference compared with the ESBL-positive BSI cohort. 
b
 Average cost weight points for episodes in cohort. 
c
 Sum of cost weight points for all episodes in cohort. 
amount potentially billable for that acute care episode.28 For 
each patient in acute care at the time of BSI detection, we 
extracted the individual, itemized costs and the cost weighting 
of their acute care stay. We also selected an alternate com-
parator group by matching each ESBL-positive patient with 
2 patients from the non-BSI cohort on the basis of sex, age, 
and identical DRG. The case mix (sum of cost weights) and 
case mix index (average cost weight) for each cohort was 
calculated. Two measures were used to compare the economic 
burden of each cohort from the hospital perspective: (1) the 
difference between costs incurred and the potentially billable 
amount and (2) the costs incurred per cost weight unit. 
Predictive Model 
On the basis of data from 2004-2010 published by Anresis.ch, 
the Swiss center for surveillance of antibiotic resistance, we 
used linear regression to fit a predictive model for the burden 
of BSI due to third-generation cephalosporin-resistant Esch-
erichia coli and Klebsiella pneumoniae throughout Switzer-
land.29 After extrapolating available data nationally, we used 
this model to estimate the number of BSIs due to these isolates 
from 2011 to 2015. This figure was then multiplied by our 
estimate of the excess LOS attributable to ESBL positivity to 
derive the national burden of resistance from the hospital 
perspective. The average cost of a bed-day in Switzerland was 
estimated from Swiss Federal Office of Statistics reports for 
2010 by dividing the total charges for hospital care by the 
total number of bed-days, after excluding psychiatric care.30 
This model incorporates 3 main assumptions: (1) that the 
excess LOS attributable to ESBL positivity among Entero-
bacteriaceae in our institution was equivalent to that of third-
generation cephalosporin resistance among E. coli and K. 
pneumoniae throughout Switzerland, (2) that the number of 
BSIs due to these 2 bacteria each year will remain constant, 
and (3) that diagnostic testing and empiric antibiotic treat-
ment remain constant. 
RESULTS 
Thirty-nine patients with ESBL-positive BSI and 113 patients 
with ESBL-negative BSI were initially included. After exclud-
ing episodes without acute care admission and 1 patient 
treated without curative intent, 30 ESBL-positive and 96 
ESBL-negative inpatient episodes remained. These involved 
124 patients, with 2 patients included twice. The median age 
was 68 (interquartile range [IQR], 55-78) years, 81 (64%) 
were male, and 68 (54%) of the infections were community 
acquired. The proportion of infections that were healthcare 
associated was similar for ESBL-negative and ESBL-positive 
infections (P = .36). Notably, 47% of patients with ESBL-
positive BSI received inappropriate initial antibiotic treat-
ment, compared with 25% of those with ESBL-negative BSI 
(P = .024). In each group, 3 patients never received appro-
priate antibiotic treatment. For those who did, the median 
delay from BSI until appropriate antibiotic therapy was 15 
(IQR, 3-43) and 11 (IQR, 4-23) hours for ESBL-positive and 
ESBL-negative BSI, respectively (P = .186). Characteristics of 
patients with BSI are shown in Table 1. The non-BSI cohort 
consisted of 42,476 patients; their median age was 49 (IQR, 
27-71) years, and 19,455 (45%) were male. 
In-Hospital Mortality 
Six patients (20%) with ESBL-positive BSI and 10 patients 
(10%) with ESBL-negative BSI died (P = .17). When ad-
justed for baseline characteristics (sex, age, healthcare or com-
munity attribution, and department at time of BSI were re-
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FIGURE 2. Trends in the estimated number of bloodstream infections (BSIs) due to third-generation cephalosporin-resistant (3GCR) 
Escherichia coli and Klebsiella pneumoniae in Switzerland. Extrapolated from Anresis.ch data for 2004-2010, with future trajectories for 
2011-2015 based on linear regression analysis. 
tained), the independent effect of ESBL production on 
inpatient mortality was not significant (odds ratio, 2.8 [95% 
CI, 0.7-11.5]; P = .15). 
LOS 
The median total LOS for patients with ESBL-positive BSI 
and ESBL-negative BSI was 22.5 (IQR, 14-61) and 14.5 (IQR, 
7-32.5) days, respectively (P = .04). The results of multistate 
modeling for excess LOS are presented in Table 2. Compared 
with negative controls, BSI due to Enterobacteriaceae was 
associated with an excess LOS whether due to ESBL-positive 
or ESBL-negative isolates. BSI due to ESBL-negative bacteria 
did not significantly decrease the hazard of discharge after 
adjustment for confounding (HR, 0.90 [95% CI, 0.74-1.10]). 
However, ESBL positivity was associated with 6.8 days of 
excess LOS compared with ESBL-negative BSI and a signif-
icantly reduced hazard of discharge (HR, 0.62 [95% CI, 
0.43-0.89]). 
Cost 
The estimated cost for provision of an occupied bed-day in 
2009 was CHF 1,391 on average for all acute care and non-
acute care beds. This means that ESBL positivity leads to an 
excess cost of CHF 9,473 per BSI due to Enterobacteriaceae. 
For the 30 patients with ESBL-positive BSI in 2009, this 
amounts to a total burden of CHF 284,190 from the hospital 
perspective. 
For patient-level cost analysis, 26 and 83 patients were 
included from the ESBL-positive and ESBL-negative cohorts, 
respectively. In addition, 51 patients from the non-BSI cohort 
were matched with the ESBL-positive patients on the basis 
of age, sex, and DRG. The costs, case mix index, and cost 
per cost weight for these cohorts are presented in Table 3. 
The average loss, calculated as the difference between costs 
incurred in the provision of care and the amount potentially 
billable from health insurance companies per acute care ep-
isode for patients in the ESBL-positive BSI, ESBL-negative 
BSI, and control cohorts, was CHF 48,674, 48,131, and 
13,532, respectively. The cost incurred per cost weight point 
for the ESBL-positive BSI, ESBL-negative BSI, and DRG-
matched groups were CHF 31,725, 33,859, and 17,044, re-
spectively, demonstrating that both BSI cohorts represent 
resource-intensive subgroups from a hospital accounting per-
spective. As a benchmark, the average cost incurred per cost 
weight point for public patients admitted to HUG in 2009 
was CHF 12.708.31 
Predictive Model 
Both visual inspection and the coefficients of determination 
(R2) supported application of a linear regression model: 98% 
and 83% of the variation in the number of BSIs due to third-
generation cephalosporin-resistant E. coli and K. pneumoniae, 
respectively, could be explained by the year alone during the 
period 2004-2010 (Figure 2). For E. coli and K. pneumoniae, 
the regression coefficients were 0.57 and 0.45, respectively. 
This model estimated that the proportion of third-generation 
cephalosporin-resistant isolates causing BSI would increase 
from 4.0% in 2010 to 6.7% in 2015. During the same period, 
the number of bed-days attributable to third-generation 
cephalosporin resistance nationally would increase from 1,300 
in 2010 to 2,200 in 2015, equivalent to an accounting cost 
increase from CHF 2,084,000 to 3,526,000. 
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D I S C U S S I O N 
In patients experiencing BSI due to Enterobacteriaceae, we 
found that ESBL production is associated with a significant 
excess LOS and, hence, economic burden from the hospital 
perspective. To our knowledge, this is the first study to employ 
multistate modeling in the estimation of excess LOS attrib-
utable to ESBL production outside the ICU setting. The 
strength of this approach is that it accounts for time depen-
dency and competing outcomes. In contrast, neither adjust-
ment for time to infection as baseline covariate or matching 
for time to infection can adequately account for time-
dependent bias while still including all eligible patients.7,12 
There are several possible explanations why antimicrobial 
resistance could be associated with increased LOS.32 The first 
is inadequate controlling for confounding covariates intrinsic 
to either the patient, such as severity of illness and comorbid 
conditions, or the infecting agent, such as the presence of a 
hypervirulent ESBL-positive clone.33 The second is treatment 
related, such as delay of appropriate antimicrobial therapy,6,34 
increased treatment toxicity (such as renal impairment sec-
ondary to aminoglycosides), need for surgery, or lack of an 
active oral agent to facilitate early discharge with outpatient 
completion of antibiotic therapy. In our study, patients with 
ESBL-positive BSI were less likely to receive appropriate an-
tibiotic treatment within 24 hours (Table 1). 
The key features and results of recent studies reporting the 
excess LOS and cost associated with ESBL-production or 
third-generation cephalosporin resistance among Enterobac-
teriaceae are listed in Table 4. In a single-center retrospective 
study, Tumbarello et al35 found that ESBL production in E. 
coli causing BSI was associated with an excess LOS of 7 days 
and a cost of €5,026 (CHF 7,634 in 2009). De Kraker et al36 
performed a multicenter prospective matched cohort study 
involving 13 European hospitals and estimated an excess LOS 
of 5 days attributable to third-generation cephalosporin re-
sistance in BSIs caused by E. coli. While both are otherwise 
robust studies, we would contend that neither the direct com-
parison of post-BSI-onset LOS between ESBL and non-ESBL 
BSI used by the former study or the matching and adjustment 
used by the latter adequately account for time-dependent bias. 
Regardless, the estimates of excess LOS attributable to ESBL-
producing bacteria in those studies are close to ours (Table 
4). Interestingly, data from the latter study were used to in-
form a recent estimate of the cost of BSI due to ESBL-positive 
E. coli in Europe as €18.1 million.37 
This study has several limitations. First, the single-center 
setting limits external validity. Generalizability would be sen-
sitive, for example, to local variation in empiric antibiotic 
therapy for sepsis and frequency of inadequate initial anti-
microbial therapy. Second, we did not take into account in-
fections other than BSI. This increased the specificity of true 
infection among included patients but underestimated the 
total burden of infections caused by ESBL-positive Entero-
bacteriaceae. Third, we estimated the economic burden of 
ESBL production as the product of the excess LOS attributed 
to ESBL positivity and the average accounting cost of a bed-
day, including fixed and variable costs.7 This standard tech-
nique does not account for the fact that fixed costs cannot 
be regained by the hospital in the short term and may there-
fore provide an overestimate of the economic burden of re-
sistance.7,8 In contrast, episodes of readmission were not ex-
amined and costs from patient and community perspectives 
were not considered, thereby underestimating the total 
burden. 
In summary, this study found that ESBL positivity con-
ferred a significant health and economic burden among pa-
tients with BSI caused by Enterobacteriaceae. Future research 
should test the generalizability of this result and advance the 
techniques used to estimate the opportunity cost of anti-
microbial resistance. Regardless, this study provides useful 
information for those seeking financial support for interven-
tions to reduce the dissemination of ESBL-positive Entero-
bacteriaceae. 
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